|Mr. Hoi Shan Tsoi||Exec. Chairman||3.86M||N/A||39|
|Mr. Wing Hon Leung FCPA, CPA||Vice Chairman, Chief Financial Officer and Company Sec.||3.74M||N/A||55|
|Ms. Su Yan Zhu||VP and Exec. Director||2.67M||N/A||52|
|Ms. Xian Hong Zou||VP and Exec. Director||2.65M||N/A||52|
|Ms. Siu Chit Choy||Global Director of Intermediate & Bulk Medicine and Exec. Director||2.12M||N/A||44|
The United Laboratories International Holdings Limited, an investment holding company, manufactures and sells pharmaceutical products. It operates in three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers antibiotic and non-antibiotic finished products, insulin products, and soft capsules casings, as well as produces and sells bulk medicines, pharmaceutical intermediate products, and organic fertilizers. It is also developing biological preparations, including insulin degludec and liraglutide; and chemical pharmaceuticals comprising antidiabetic drugs, anti-cancer drugs, anti-HBV drugs, and high-end antibiotics. In addition, the company trades in pharmaceutical products. It operates primarily in the People's Republic of China, Europe, India, Hong Kong, the Middle East, South America, other Asian regions, and other regions. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited operates as a subsidiary of Heren Far East Limited.
The United Laboratories International Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.